Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $60,039.28 in Stock

Key Points

• Zhenyu Xu sold 7,394 SOPHiA GENETICS shares for approximately $60,039 at an average price of $8.12. The pre-arranged Rule 10b5-1 transaction was intended to cover tax withholding tied to vested equity awards, leaving Xu with 545,493 shares.
• SOPH shares traded at $7.15, below the $10.00 analyst consensus price target, while the company reported $23.31 million in quarterly revenue but missed estimates on adjusted earnings and remained deeply unprofitable.
• Analyst sentiment is mixed, with three Buy ratings, one Hold and one Sell; institutional investors own approximately 31.59% of the company’s stock.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Zhenyu Xu sold 7,394 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $8.12, for a total transaction of $60,039.28. Following the completion of the sale, the insider owned 545,493 shares in the company, valued at approximately $4,429,403.16. The trade was a 1.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total transaction of $89,100.00.
• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total transaction of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00.
• On Monday, July 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $22,800.00.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH traded down $0.23 during mid-day trading on Wednesday, hitting $7.15. The company had a trading volume of 432,750 shares, compared to its average volume of 308,157. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The business's 50-day simple moving average is $7.82 and its 200-day simple moving average is $6.12. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The firm has a market cap of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. As a group, analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Brokerages reportedly have a consensus price target of $10.00 for SOPHiA GENETICS, suggesting potential upside from recent trading levels if the company meets analyst expectations. SOPHiA GENETICS SA Stock Has Consensus Target Price of $10.00 According to Brokerages
• Neutral Sentiment: A comparison article examined SOPHiA GENETICS against Weave Communications, but the item did not identify a specific new company development or change to SOPH’s outlook. Critical Comparison: Weave Communications vs. SOPHiA GENETICS
• Negative Sentiment: Company insiders collectively sold approximately 82,298 shares worth $668,827, including sales by Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma and other executives. The transactions reduced their individual holdings by roughly 0.15% to 3.55%, creating near-term selling pressure and potentially weighing on investor sentiment. However, all reported sales were pre-arranged and explicitly made to satisfy tax obligations rather than indicating discretionary selling. SEC insider transaction filing

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company's stock worth $257,000 after purchasing an additional 4,155 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company's stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. First Dallas Securities Inc. acquired a new stake in shares of SOPHiA GENETICS in the first quarter valued at approximately $50,000. 1492 Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company's stock valued at $1,117,000 after purchasing an additional 17,406 shares in the last quarter. Finally, Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. Institutional investors own 31.59% of the company's stock.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a research note on Tuesday, July 21st. BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Finally, HC Wainwright lifted their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company's principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.